Analysis of three HLA-A*3303 binding peptide anchors using an HLA-A*3303 stabilization assay

被引:17
|
作者
Takiguchi, M
Matsuda, T
Tomiyama, H
Miwa, K
机构
[1] Kumamoto Univ, Ctr AIDS Res, Div Viral Immunol, Kumamoto 8620976, Japan
[2] Ajinomoto Pharmaceut Res Labs, Kawasaki, Kanagawa, Japan
来源
TISSUE ANTIGENS | 2000年 / 55卷 / 04期
关键词
HLA-A*3303; HLA class I molecules; peptide;
D O I
10.1034/j.1399-0039.2000.550402.x
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The affinity of 232 8- to Il-mer peptides carrying HLA-A*3303 anchor residues at position 2 (P2) (Ala, lie, Leu, Val, Phe or Tyr) and the C-terminus (Arg) was analysed by a stabilization assay using RMA-S transfectants expressing HLA-A*3303 and human beta(2)-microglobulin. One hundred and nineteen of these peptides (51.3%) bound to HLA-A*3303, confirming that these residues are anchors for HLA-A*3303. Evaluation of P2 residues demonstrated that binding of peptides with Phe or Tyr at P2 is stronger than that of peptides with aliphatic hydrophobic residues at P2. This was confirmed by analysis of a panel of peptides mutated at P2, Analysis of the C-terminal mutant peptides showed that substitution of Lys for Arg had minimal influence on binding to HLA-A*3303. This implies that peptides carrying HLA-A*1101 anchor residues (Val, Ile, Phe or Tyr at P2 and Lys at the C-terminus) can bind to ISLA-A*3303. However, such peptides showed lower binding for HLA-A*3303 than for HLA-A*1101. Thus, Arg at the C-terminus is much stronger anchor for HLA-A*3303 than Lys. The preference for Arg and Lys at the C-terminus by HLA-A*1101 and HLA-A*3303 respectively may be due to sequences of three residues (70, 97 and 114) forming the F-pocket of these HLA class I molecules. Statistical analysis of 232 peptides further showed a positive effect of negatively charged residues at P1 for peptide binding to HLA-A*3303. Thus, residues at P1, P2 and the C-terminus play an important role in peptide binding to HLA-A*3303.
引用
收藏
页码:296 / 302
页数:7
相关论文
共 50 条
  • [1] Polarity of the P1 anchor residue determines peptide binding specificity between HLA-A*3101 and HLA-A*3303
    Takiguchi, M
    Matsuda, T
    Tomiyama, H
    [J]. TISSUE ANTIGENS, 2000, 56 (06): : 501 - 506
  • [2] HLA-A*3303 and*3301 predispose patients to persistent hepatitis B infection
    Ramezani, Amitis
    Aghakhani, Arezoo
    Kalantar, Ebrahim
    Banifazl, Mohammad
    Eslamifar, Ali
    Velayati, Ali Akbar
    [J]. JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES, 2009, 18 (01) : 117 - 118
  • [3] Identification of a new HLA-A*3301 and HLA-A*3303 restricted cytomegalovirus-specific CD8+T lymphocyte epitope.
    Lim, JB
    Provenzano, M
    Bettinotti, M
    Caruccio, L
    Nalgosen, D
    Stroncek, D
    [J]. BLOOD, 2003, 102 (11) : 724A - 724A
  • [4] Peptide-binding motif of HLA-A*6603
    Christina Bade-Doeding
    Britta Eiz-Vesper
    Constanca Figueiredo
    Axel Seltsam
    Holger-Andreas Elsner
    Rainer Blasczyk
    [J]. Immunogenetics, 2005, 56 : 769 - 772
  • [5] The peptide-binding motif of HLA-A*0217
    Savoie, CJ
    Kamikawaji, N
    Sasazuki, T
    [J]. IMMUNOGENETICS, 1999, 49 (06) : 567 - 570
  • [6] The peptide-binding motif of HLA-A*0217
    Christopher J. Savoie
    Nobuhiro Kamikawaji
    T. Sasazuki
    [J]. Immunogenetics, 1999, 49 : 567 - 570
  • [7] Peptide-binding motif of HLA-A*6603
    Bade-Doeding, C
    Eiz-Vesper, B
    Figueiredo, C
    Seltsam, A
    Elsner, HA
    Blasczyk, R
    [J]. IMMUNOGENETICS, 2005, 56 (10) : 769 - 772
  • [8] A roadmap for HLA-A, HLA-B, and HLA-C peptide binding specificities
    Chelvanayagam, G
    [J]. IMMUNOGENETICS, 1996, 45 (01) : 15 - 26
  • [9] Characterization of three new alleles HLA-A*02:241, HLA-A*02:242 and HLA-A*30:04:02
    Heyder, J.
    Heinold, A.
    Kudlek, E.
    Opelz, G.
    Tran, T. H.
    [J]. TISSUE ANTIGENS, 2011, 78 (02): : 152 - U100
  • [10] A new HLA-A Allele, HLA-A*6824, identified in three unrelated individuals
    Davey, S
    Carter, V
    Goodman, R
    Day, S
    Brown, C
    Morris, J
    Key, T
    Bendukidze, N
    Dunn, PPJ
    [J]. TISSUE ANTIGENS, 2005, 65 (05): : 485 - 487